These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31380273)

  • 41. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Sands J; Li Q; Hornberger J
    Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
    Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
    Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
    Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ultra-sensitive
    Vendrell JA; Mazieres J; Senal R; Rouquette I; Quantin X; Pujol JL; Roch B; Bouidioua A; Godreuil S; Coyaud E; Brousset P; Solassol J
    Clin Cancer Res; 2019 Jul; 25(14):4280-4289. PubMed ID: 30936123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Dynamic Use of
    Macías M; Alegre E; Alkorta-Aranburu G; Patiño-García A; Mateos B; Andueza MP; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; González Á
    Dis Markers; 2019; 2019():7954921. PubMed ID: 30809319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.
    Asaka S; Yoshizawa A; Saito K; Kobayashi Y; Yamamoto H; Negishi T; Nakata R; Matsuda K; Yamaguchi A; Honda T
    Int J Oncol; 2018 Jun; 52(6):2110-2118. PubMed ID: 29620164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Two
    Kim JO; Shin JY; Kim SR; Shin KS; Kim J; Kim MY; Lee MR; Kim Y; Kim M; Hong SH; Kang JH
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients.
    Xiong L; Cui S; Ding J; Sun Y; Zhang L; Zhao Y; Gu A; Chu T; Wang H; Zhong H; Ye X; Gu Y; Zhang X; Hu M; Jiang L
    Oncotarget; 2017 Sep; 8(38):63846-63856. PubMed ID: 28969034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Detection of epidermal growth factor receptor gene mutations in different types of non-small cell lung cancer by droplet digital PCR and amplification refractory mutation system].
    Li R; Ye SB; He Y; Wang X; Wu N; Xia QY; Shen Q; Shi SS
    Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):764-768. PubMed ID: 29136689
    [No Abstract]   [Full Text] [Related]  

  • 57. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
    Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
    Kim Y; Shin S; Lee KA
    Cancer Cell Int; 2021 Jan; 21(1):50. PubMed ID: 33435996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.